Skip to main content
OpenTrials
Completed

NCT Number: NCT06948292

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Kidney Disease Stages 3-5 Diabetes Complications Diabetes Mellitus Diabetic Kidney Disease Diabetic Nephropathies Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hypertensive Kidney Disease Hypertensive Nephropathy Kidney Diseases Male Urogenital Diseases Pathological Conditions, Signs and Symptoms Proteinuria Signs and Symptoms Urination Disorders Urogenital Diseases Urologic Diseases Urological Manifestations

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Neukidney Inc

Pasedena, Texas, 77504, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with Chronic kidney disease stage 3-5
  • Estimated Glomerular function by MDRD of less than 60mls/min
  • Patients with declining renal function ( as measured by eGFR by MDRD )
  • Rate of decline of eGFR over the last one year of less than 20%
  • Negative Serology markers for CKD etiology
  • Provider perceived adherence to study follow- up

Exclusion criteria

  • Rapid rate of decline in kidney function of > 10 % over 3 months
  • Symptomatic renal failure
  • Presence of any suspected Acute renal failure superimposed
  • Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
  • No known reversible cause of renal decline

Treatment and study plan

QRX-3

Drug

phase 2B CKD study

Primary outcomes

  1. daily change in glomerular filtration rate by creatinine in mls/min

    Time frame: 12 months

    mean change in glomerular filtration rate by creatinine in mls/min in one year compare to baseline at screening

Secondary outcomes

  1. change in proteinuria by mg/g

    Time frame: 12 months

    change in mean proteinuria measured by random urine protein/creatinine ratio at 12 months compare to control will be compared in both groups

Sponsors and collaborators

Lead sponsor

Ebima Clifford Okundaye

Industry

Registry information

Official study title

Role of QRX-3 a Novel NAD Modulator in Ambulatory Chronic Kidney Patients

Acronym: QRX-3 in CKD

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 29, 2025
Registry last updated
Sep 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.